Loading clinical trials...
Loading clinical trials...
Poor prognosis dufuse large B-cell lymphoma (DLBCL) represents 50% of all DLBCL with overall cure rates ranging from 50-60% with modern dose-dense immunochemotherapy regimens such as R-CHOP14. Using a...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Hospital Universitario Principe de Asturias
NCT07397832 · Diffuse Large B-Cell Lymphoma (DLBCL)
NCT06043011 · Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL), and more
NCT06828991 · Diffuse Large B-Cell Lymphoma (DLBCL)
NCT03936153 · Diffuse Large B-cell Lymphoma (DLBCL)
NCT06832228 · Diffuse Large B-cell Lymphoma (DLBCL)
Principe de Asturias University Hospital
Alcalá de Henares, Madrid
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions